ZYBERNO
Stock Report
Updated Sep 1, 2026

Seres Therapeutics, Inc. (MCRB)

Healthcare • NASDAQ

$4.91

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
19.0/100
POOR BUSINESS
Seres Therapeutics, Inc. (MCRB) scores 19/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-25.9%)
Debt-to-Equity (Solvency Risk):CRITICAL (3.28x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-83.4%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Seres Therapeutics, Inc. (MCRB) stock report — Zyberno Score 19/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, MCRB generated -$42.37M in Owner Earnings. Capital was deployed as follows: $218.00K invested in capital expenditures. Reinvestment rate: -17.6%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:4.91
Market Cap:$47.66M

Valuation Multiples (3)

P/B Ratio:1.38x
P/S Ratio:60.40x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$88.71M

Price Action & Momentum (3)

Momentum Percentile:17 / 100
% of 52-Week High:16.4%
B. Profitability Assessment

Return Metrics (5)

ROA:-7.7%
Reinvestment Rate:-17.6%
Fundamental Growth Rate (g):14.7%

Margin Analysis (1)

Ebitda Margin:-10,213.6%

Yield Metrics (2)

Earnings Yield:-$21.65
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:118.9%
Latest Earnings Filed:2026-08-05

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):-45.9%

Earnings Growth (Linear) (1)

Net Income Growth Rate (Linear):-50.0%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:2.11x
Quick Ratio:2.11x
Cash Ratio:0.78x

Leverage Analysis (3)

Debt To Equity Ttm:3.28x
Debt-to-Equity Ratio:3.28x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:22,317,000.00
Cash And Cash Equivalents:15,594,000.00
Long Term Debt:$44.82M
Net Debt:$41.05M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $789.00K
Linear Growth: -45.9%
📊 Click to view full MCRB Revenue analysis & methodology →
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$84.03M

Bottom Line Performance (3)

Net income TTM: -$9.64M
Linear Growth: -50.0%
📊 Click to view full MCRB Net Income analysis & methodology →
Income Before Tax:$0.00
Ebitda Ttm:-80,585,000.00

Operating Expenses (5)

Operating Expenses:85,917,000.00
R And D Expense:46,636,000.00
Sga Expense:32,146,000.00
Income Tax Expense:$0.00
Interest Expense:-8,110,000.00

Expense Ratios (3)

R And D To Revenue Percentage:6,336.4%
Sga To Revenue Percentage:4,367.7%
Ebitda Margin:-10,213.6%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$101.59M
Current Assets:$42.35M
Ppe Net:61,093,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:67,054,000.00
Current Liabilities:20,031,000.00
Long Term Debt:$44.82M
Short Term Debt:$11.83M

Equity & Capital (3)

Equity:$34.53M
Retained Earnings:-$987.74M
Common Stock:360,000,000.00

Working Capital Items (3)

Accounts Receivable:274,000.00
Inventory:0.00
Accounts Payable:1,186,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:1,739,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$42.15M-$42.37M

Investment Activities (2)

Investing Cash Flow:$0.00
Capital Expenditures Ttm:218,000.00

Financing Activities (3)

Financing Cash Flow:$428.00K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:27,525,000.00
Long Term Debt Issuance:$103.38M
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:3,449,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-0.97
Eps diluted TTM: -$0.97
Linear Growth: 21.3%
📊 Click to view full MCRB EPS analysis & methodology →
Earnings Per Share Ttm:-$0.99

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.08
Operating Cash Flow Per Share:$0.12

Book Value & Capital (2)

Book Value Per Share:$3.56
Cash Per Share:1.61

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.01x
Working Capital Turnover Ttm:0.04x

Receivables Management (2)

Receivables Turnover Ttm:2.88x
Days Sales Outstanding Ttm:126.76

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:548.66
Cash Conversion Cycle:-1,420.90
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:40.00
Quality Score:70.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$42.37M

Damodaran Growth Analysis (2)

Reinvestment Rate:-17.6%
Fundamental Growth Rate (g):14.7%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (2)

Revenue Growth Rate (Linear):-45.9%
Net Income Growth Rate (Linear):-50.0%

Other Growth Rates (1)

Book Value Growth Rate (Linear):-7.4%
C. Company Profile & Context

Corporate Information (6)

Symbol:MCRB
Company Name:Seres Therapeutics, Inc.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:9.71M
Shares Outstanding Basic:9.71M
Shares Outstanding Diluted:9.75M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 00:26:39 UTC
Data Timestamp:2026-08-20T05:24:17.069354
Scroll to Top